Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REBACIN for regression of high-grade cervical squamous intraepithelial lesions
ChiCTR1800015617Phase 4Not yet recruiting
- Sponsor
- Tianjin First Central Hospital
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ribostamycin in cervical intraepithelial neoplasia (CIN) and human papillomavirus infection, sponsored by Tianjin First Central Hospital. Primary endpoint: Cervical biopsy pathology. Planned start Jun 2018; status: not yet recruiting.
02
Drugs
ribostamycin
03
Conditions
cervical intraepithelial neoplasia (CIN)human papillomavirus infection
Beyond the preview
Go deeper on ChiCTR1800015617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015617.